Aprea Therapeutics Inc. (APRE): Analysts giving this a price target of $...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	1004
Posts	43212
Boards Moderated	0
Alias Born	03/17/2014

Hercules1

Re: None

Tuesday, 07/18/2023 1:10:56 PM

Tuesday, July 18, 2023 1:10:56 PM

Analysts giving this a price target of $20.

Yes $20.

Let that sink in.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent APRE News

Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 10:01:02 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/05/2024 05:15:27 AM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:26:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:13:27 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 11:03:59 AM
Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:16:01 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/09/2023 09:20:51 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:35 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 11:31:14 AM
Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 12:30:20 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 01:52:29 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 01:50:02 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 01:48:22 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/24/2023 12:00:28 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 11:39:02 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:36:21 AM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/11/2023 11:30:29 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:01:07 PM
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference • GlobeNewswire Inc. • 06/14/2023 12:00:00 PM
Aprea Therapeutics to Present at BIO International Convention • GlobeNewswire Inc. • 05/30/2023 12:30:00 PM
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations • GlobeNewswire Inc. • 05/15/2023 08:05:00 PM
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors • GlobeNewswire Inc. • 05/08/2023 12:00:00 PM

More APRE News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover